Rannim Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 26 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.41 M
- Revenue Growth -11.95%
- Profit Growth -13.30%
- Ebitda -24.97%
- Net Worth 4.46%
- Total Assets 3.85%
About Rannim Pharmaceuticals
Rannim Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 August 1998 and has a history of 26 years and six months. Its registered office is in Gojhariya, Gujarat, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.41 M.
Mukesh Khamar and Ankit Khamar serve as directors at the Company.
Company Details
- Location
Gojhariya, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231GJ1998PTC034535
- Company No.
034535
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Aug 1998
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
What products or services does Rannim Pharmaceuticals Private Limited offer?
Rannim Pharmaceuticals Private Limited offers a wide range of products and services, including Bird Food, Poultry & Animal Food, Animal Feed Supplement.
Who are the key members and board of directors at Rannim Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukesh Khamar  | Director | 18-Aug-1998 | Current |
| Ankit Khamar | Additional Director | 19-Dec-2011 | Current |
Financial Performance of Rannim Pharmaceuticals.
Rannim Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 11.95% decrease. The company also saw a substantial fall in profitability, with a 13.3% decrease in profit. The company's net worth moved up by a moderate rise of 4.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rannim Pharmaceuticals?
In 2023, Rannim Pharmaceuticals had a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.41 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.54 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 May 2024 | Others | ₹2.50 M | Open |
| 20 Dec 2018 | Others | ₹2.91 M | Open |
How Many Employees Work at Rannim Pharmaceuticals?
Unlock and access historical data on people associated with Rannim Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rannim Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rannim Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
